Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting.
As antifungal agents are frequently used in hematology and oncology, economic data on the empirical therapy of suspected systemic fungal infection are pivotal. Data were analyzed according to: (1) the rate of nephrotoxicity related to treatment with caspofungin in comparison to liposomal amphotericin B (L-AmB) from a randomized clinical trial, (2) the effect of nephrotoxicity on length of hospital stay from a European observational study, and (3) an example of total bottom-up cost in a department of hematology in Germany. All estimates include 95% confidence intervals (CI) using two-stage Monte Carlo simulation on binominal and Gaussian random variables from separate studies with comparable populations. Overall, 8.9 (95% CI 5.9-12.1) fewer patients (of 100 randomized) experienced worsening of renal function with caspofungin vs L-AmB, giving a number needed to treat for one patient to be harmed by L-AmB of 12 (95% CI 8-17). This was estimated to translate into 5.3 extra days in hospital (95% CI 1.6-9.1) per event or 0.48 days (95% CI 0.14-0.88) worth 298 euro (95% CI 89-554) per patient receiving L-AmB rather than caspofungin. From the hospital perspective, use of caspofungin was estimated to be cost-neutral compared to L-AmB at a per diem total hospital cost of 428 euro with, and 1284 euro without, consideration of supplementary reimbursement (Zusatzentgelt) of both L-AmB and caspofungin. The data presented in this scenario show that use of caspofungin in hematology-oncology departments in Germany results in shorter hospital stays and is at least cost-neutral compared to use of L-AmB.
Kaskel
Peter
P
Outcomes Research, MSD Sharp and Dohme GmbH, Haar, Germany. peter_kaskel@msd.de
Tuschy
Silja
S
Wagner
Alexander
A
Bannert
Christian
C
Cornely
Oliver A
OA
Glasmacher
Axel
A
Lipp
Hans-Peter
HP
Ullmann
Andrew J
AJ
D000666:Amphotericin B / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000077336:Caspofungin; D003365:Costs and Cost Analysis; D004311:Double-Blind Method; D054714:Echinocandins / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D005858:Germany; D006801:Humans; D055666:Lipopeptides; D008081:Liposomes; D008137:Longitudinal Studies; D009181:Mycoses / Q000188:drug therapy* / Q000517:prevention & control; D011446:Prospective Studies
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008081:Liposomes; D000666:Amphotericin B; D000077336:Caspofungin